Riluzole microencapsulated - Orbis Biosciences
Alternative Names: ORB-111Latest Information Update: 28 Jun 2023
At a glance
- Originator Orbis Biosciences
- Class Benzothiazoles; Neuroprotectants; Small molecules
- Mechanism of Action Excitatory amino acid antagonists; Glutamate release inhibitors; Voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (PO, Powder)
- 04 May 2020 Orbis Biosciences has been acquired by Adare Pharmaceuticals
- 29 May 2019 Orbis Biosciences has patent applications covering taste masked drug formulations, in USA, Japan, Europe, as well as a world application